You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Secondary AML: t-AML and AML-MRC

Some types of acute myeloid leukemia (AML) may develop from specific causes. This is called secondary AML (sAML). Therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC) are 2 different types of sAML. Approximately 30% of all AML cases are diagnosed as either t-AML or AML-MRC.

Watch the video below to learn more about sAML subtypes t-AML and AML-MRC.

See more important AML facts.

Treatment for t-AML and AML-MRC

t-AML and AML-MRC are usually treated with chemotherapy. VYXEOS (vix-e-ose) is an advancement in chemotherapy that specifically treats adults who have been newly diagnosed with t-AML or AML-MRC. VYXEOS is a combination of 2 chemotherapies (daunorubicin and cytarabine) in tiny, bubble-like carriers called liposomes.


VYXEOS is an intravenous (IV) chemotherapy used for the treatment of certain types of newly-diagnosed acute myeloid leukemia (AML) in adults and pediatric patients 1 year and older, including patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders (also called AML with myelodysplasia-related changes, AML-MRC).


Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.